Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asenapine

Drug Profile

Asenapine

Alternative Names: Asenapine maleate; Atisenap; ME2136; ORG-5222; Saphris; SCH-900274; Sycrest

Latest Information Update: 14 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Organon
  • Developer AbbVie; Lundbeck A/S; Meiji Seika Pharma; Merck & Co
  • Class Antipsychotics; Heterocyclic compounds with 4 or more rings; Oxepins; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Alpha adrenergic receptor antagonists; Dopamine receptor antagonists; Histamine H1 receptor antagonists; Serotonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Schizophrenia

Most Recent Events

  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 24 Jun 2018 Biomarkers information updated
  • 20 Jul 2017 Merck terminates a phase II trial as the funding ended due to recruitment delays for Bipolar disorders in USA (PO) (NCT01807741)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top